GRFS vs NXTS vs ARGX Stock Comparison

Grifols, Nexentis Technologies and Argenx Se Prices as of Oct 27, 2026 Peers: Industry group
GRFS Grifols SA
$8.10 +10.2% 1M -13.6% 1Y
Market cap
$5.51B
P/E
12.1x
Revenue (TTM)
—
Div. yield
1.36%
Biotechnology Healthcare
3 wins
ARGX Argenx Se
$882.48 -8.0% 1M +6.3% 1Y
Market cap
$54.61B
P/E
28.8x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
4 wins

Head to Head

7 decided of 12

Argenx Se leads on 4 of the 12 questions below (Argenx Se 4, Grifols 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGRFSNXTSARGXLeader
Larger companyMarket capitalisation $5.51B $473.36K $54.61B ARGX
Cheaper on earningsLower P/E, profitable companies only 12.1x 0.0x 28.8x GRFS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 8.6x — 28.8x GRFS
Faster revenue growthRevenue growth, trailing twelve months — — +61.5% –
More profitableNet margin, trailing twelve months — — 32.3% –
Better return on capitalReturn on invested capital — — — –
Less leveragedLower net debt / EBITDA — 1.6x — –
Higher dividend yieldTrailing dividend yield 1.36% — — –
Better 1-year returnPrice return, last 12 months -13.6% -97.8% +6.3% ARGX
Better 5-year returnAnnualised price return, 5 years -9.4%/yr -86.1%/yr +25.8%/yr ARGX
Less volatileAnnualised volatility, 1 year 32.4% 168.9% 36.9% GRFS
Higher overall scoreMean of the five percentile scores vs peers 56/100 32/100 92/100 ARGX

Percentile Scorecard

GRFSNXTSARGX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGRFSNXTSARGX
Valuation 99 #7 of 625 – 84 #99 of 625
Growth – 13 #523 of 602 94 #35 of 602
Profitability – 40 #329 of 551 98 #11 of 551
Financial Health 14 #564 of 656 43 #372 of 656 –
Shareholder Returns 56 #161 of 365 – –
Overall 56 32 92
  • GRFS ranked among 672 companies in Pharmaceuticals and Biotechnology
  • NXTS ranked among 672 companies in Pharmaceuticals and Biotechnology
  • ARGX ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGRFSNXTSARGXSPY
1 month +10.2%-60.5%-8.0% -0.2%
3 months +1.2%-62.6%+1.2% +3.9%
6 months +0.4%-87.8%+13.9% +8.2%
Year to date -13.4%-95.1%+4.9% +12.9%
1 year -13.6%-97.8%+6.3% +12.3%
3 years +3.3%-99.9%+91.9% +87.4%
3 years, per year +1.1%-89.5%+24.3% +23.3%
5 years -39.0%-100.0%+214.2% +67.9%
5 years, per year -9.4%-86.1%+25.8% +10.9%
10 years -44.7%-100.0%— +261.1%
10 years, per year -5.8%-66.5%— +13.7%

Risk

MeasureGRFSNXTSARGXSPY
Volatility, 1Y 32.4%168.9%36.9% 12.7%
Downside volatility, 1Y 34.1%153.3%34.6% 12.7%
Beta vs S&P 500, 1Y 0.952.330.39 1.00
Return / volatility, 1Y -0.42-0.580.17 0.97
Max drawdown, 5Y -58.8%-100.0%-38.2% -25.4%
From 52-week high -16.7%-97.8%-16.7% -1.2%
52-week high $9.72$26.04$1,058.90 $779.14
52-week low $7.02$0.53$663.93 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGRFSNXTSARGX
P/E now vs peer median 12.1xmedian 17.2x 0.0xmedian 17.2x 28.8xmedian 17.2x
P/S now vs peer median 0.6xmedian 9.0x —median 9.0x 9.4xmedian 9.0x
EV/EBITDA now vs peer median —median 16.3x 1.5xmedian 16.3x —median 16.3x
P/FCF now vs peer median 7.8xmedian 18.7x —median 18.7x —median 18.7x
P/B now vs peer median 0.6xmedian 2.2x 0.2xmedian 2.2x —median 2.2x
PEG now vs peer median —median 0.33 0.00median 0.33 0.27median 0.33

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGRFSNXTSARGX
Revenue – – $5.82B
Gross profit – – $5.24B
Operating income – -$5.28M $1.74B
Net income – -$14.06M $1.88B
R&D – $532.00K $1.80B
EPS (diluted) – $-17.10 $28.43
Cash & equivalents $969.15M $7.62M –
Total debt $44.00B $3.22M –
Shares (diluted) 681.57M 816.14K 66.03M
Enterprise value $4.59B -$22.29M $54.61B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGRFSNXTSARGX
P/E 12.1x 0.0x 28.8x
P/FCF 7.8x – –
P/Operating cash flow – – –
P/S 0.6x – 9.4x
P/B 0.6x 0.2x –
P/Tangible book 1.0x -0.2x –
EV/EBITDA – 1.5x –
EV/EBIT – 1.5x 31.4x
EV/Revenue – – 9.4x
EV/FCF – – –
EV/Operating cash flow – – –
PEG (3Y EPS CAGR) – 0.00 0.27

Growth

14 metrics
MetricGRFSNXTSARGX
Revenue growth (1Y) – – 61.5%
Revenue CAGR (3Y) – – 80.5%
Gross profit growth (1Y) – – 62.2%
Gross profit CAGR (3Y) – – 80.0%
Operating income growth (1Y) – -7.7% 120.6%
Operating income CAGR (3Y) – 3.0% 85.1%
Net income growth (1Y) – -48.2% 22.5%
Net income CAGR (3Y) – -35.8% 115.5%
EPS growth (1Y) – -567.8% 20.9%
EPS CAGR (3Y) – -45.2% 104.8%
Operating cash flow growth (1Y) – – –
Operating cash flow CAGR (3Y) – – –
Free cash flow growth (1Y) – – –
Free cash flow CAGR (3Y) – – –

Profitability

14 metrics
MetricGRFSNXTSARGX
Gross margin – – 90.0%
EBITDA margin – – –
Operating margin – – 29.9%
Pretax margin – – 32.6%
Net margin – – 32.3%
FCF margin – – –
Operating cash flow margin – – –
Return on equity – -157.0% –
Return on assets – -71.9% –
Return on invested capital – – –
Return on capital employed – -31.5% –
Asset turnover – – –
Cash conversion (OCF / net income) – – –
Stock comp / revenue – – –

Financial Health

11 metrics
MetricGRFSNXTSARGX
Debt / assets 48.9% 2.3% –
Debt / equity 1.3x 0.2x –
Net debt / EBITDA – 1.6x –
Debt / FCF – – –
Liabilities / assets 61.4% 89.8% –
Equity / assets 38.6% 10.2% –
Interest coverage – – 10,120x
Current ratio 2.5x 3.7x –
Quick ratio 0.8x 3.2x –
Cash ratio 0.4x 3.2x –
Altman Z-score – – –

Shareholder Returns

7 metrics
MetricGRFSNXTSARGX
Dividend yield 1.4% – –
Net buyback yield – – –
Shareholder yield 1.4% – –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGRFSNXTSARGX
Forward P/E 8.6xFY2026 – 28.8xFY2026
EPS, next fiscal year $0.94FY2026 – $30.63FY2026
EPS growth, next FY +10.6%FY2026 – +56.5%FY2026
EPS growth, the year after +26.6% – +26.9%
Revenue, next fiscal year $8.88BFY2026 – $6.08BFY2026
Revenue growth, next FY +0.0%FY2026 – +43.1%FY2026
Revenue growth, the year after +10.3% – +22.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGRFSNXTSARGX
Held by institutions 21.0% – 46.1%
Institutions holding 166 – 504
Change in shares held, QoQ -0.5% – -2.0%
Institutions buying 73 – 264
Institutions selling 65 – 160
Buyers to sellers 1.12 – 1.65

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GRFSNXTSARGX
GRFS 1.00 0.04 0.15
NXTS 0.04 1.00 0.12
ARGX 0.15 0.12 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GRFS, NXTS and ARGX?

Argenx Se (ARGX) is the largest by market capitalisation: Grifols (GRFS) $5.51B, Nexentis Technologies (NXTS) $473.36K, Argenx Se (ARGX) $54.61B.

Which stock is cheaper, GRFS, NXTS and ARGX?

Grifols (GRFS) trades on the lowest price-to-earnings ratio (Grifols (GRFS) 12.1x, Nexentis Technologies (NXTS) 0.0x, Argenx Se (ARGX) 28.8x). On next year's consensus earnings, Grifols (GRFS) is cheapest (Grifols (GRFS) 8.6x, Argenx Se (ARGX) 28.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which stock has performed better?

Over the past year Argenx Se (ARGX) returned the most: Grifols (GRFS) -13.6%, Nexentis Technologies (NXTS) -97.8%, Argenx Se (ARGX) +6.3%. Over five years, Argenx Se (ARGX) compounded fastest (Grifols (GRFS) -9.4%/yr, Nexentis Technologies (NXTS) -86.1%/yr, Argenx Se (ARGX) +25.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Grifols (GRFS) 1.36%. Nexentis Technologies (NXTS) and Argenx Se (ARGX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Grifols (GRFS) has been the steadiest (Grifols (GRFS) 32.4%, Nexentis Technologies (NXTS) 168.9%, Argenx Se (ARGX) 36.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GRFS, NXTS and ARGX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Argenx Se (ARGX) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.